Skip to main content
Top
Published in: Clinical Rheumatology 4/2008

01-04-2008 | Original Article

The clinical significance of serum N-terminal pro-brain natriuretic peptide in systemic sclerosis patients

Authors: Hyo Jin Choi, Young Kee Shin, Hyun Joo Lee, Joo Young Kee, Dong Woo Shin, Eun Young Lee, Yun Jong Lee, Eun Bong Lee, Yeong Wook Song

Published in: Clinical Rheumatology | Issue 4/2008

Login to get access

Abstract

We evaluated the clinical significance of serum N-terminal pro-brain natriuretic peptide (NT-proBNP) level in systemic sclerosis (SSc). We studied 45 SSc patients (30 with limited and 15 with diffuse cutaneous SSc) of mean age ± SD 47.1 ± 12.9 years, mean duration of disease 10.2 ± 6.0 years, and 45 age- and sex-matched healthy controls. Pulmonary artery pressure was measured by echocardiography. Lung involvement was evaluated by pulmonary function testing and by using high-resolution computed tomography scores. Serum NT-proBNP levels were measured using a sandwich electrochemiluminescent immunoassay. Serum NT-proBNP levels were significantly higher in patients with SSc compared to healthy controls. When the patients were divided into clinical subsets, serum NT-proBNP was higher in diffuse SSc than in limited SSc. Serum NT-proBNP levels were found to be positively correlated with age, skin thickness score, and systolic pulmonary artery pressure and negatively correlated with percentage of carbon monoxide diffusion capacity (DLco). Multivariate analysis showed that serum NT-proBNP levels were positively correlated with age (p = 0.010), skin thickness score (p = 0.000), and blood pressure (p = 0.021) and negatively correlated with %DLco (p = 0.016). Fifty-seven percent of the variation in log (proBNP) can be explained by the multivariate model (R 2 = 0.57). Serum NT-proBNP levels were higher in SSc patients (particularly the diffuse subset) than in healthy controls and were found to be correlated with skin thickness and %DLco. We conclude that serum NT-proBNP may be a biologic marker of skin fibrosis and pulmonary vascular involvement in SSc.
Literature
1.
go back to reference MacGregor AJ, Canavan R, Knight C, Denton CP et al (2001) Pulmonary hypertension in systemic sclerosis: risk factors for progression and consequences for survival. Rheumatology (Oxford) 40:453–457CrossRef MacGregor AJ, Canavan R, Knight C, Denton CP et al (2001) Pulmonary hypertension in systemic sclerosis: risk factors for progression and consequences for survival. Rheumatology (Oxford) 40:453–457CrossRef
2.
go back to reference James SK, Lindahl B, Siegbahn A et al (2003) N-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease; GUSTO-IV substudy. Circulation 108:275–281PubMedCrossRef James SK, Lindahl B, Siegbahn A et al (2003) N-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease; GUSTO-IV substudy. Circulation 108:275–281PubMedCrossRef
3.
go back to reference Fisher C, Berry C, Blue L, Morton JJ et al (2003) N-terminal pro B type natriuretic peptide, but not the new putative cardiac hormone relaxin, predicts prognosis in patients with chronic heart failure. Heart 89:879–881PubMedCrossRef Fisher C, Berry C, Blue L, Morton JJ et al (2003) N-terminal pro B type natriuretic peptide, but not the new putative cardiac hormone relaxin, predicts prognosis in patients with chronic heart failure. Heart 89:879–881PubMedCrossRef
4.
go back to reference Kurose M, Yoshimura M, Yasue H (1997) Raised plasma BNP in a patient with acute pulmonary thromboembolism. Heart 78:320–321PubMed Kurose M, Yoshimura M, Yasue H (1997) Raised plasma BNP in a patient with acute pulmonary thromboembolism. Heart 78:320–321PubMed
5.
go back to reference Lainchbury JG, Campbell E, Frampton CM et al (2003) Brain natriuretic peptide and N-terminal brain natriuretic peptide in the diagnosis of heart failure in patients with acute shortness of breath. J Am Coll Cardiol 42:728–735PubMedCrossRef Lainchbury JG, Campbell E, Frampton CM et al (2003) Brain natriuretic peptide and N-terminal brain natriuretic peptide in the diagnosis of heart failure in patients with acute shortness of breath. J Am Coll Cardiol 42:728–735PubMedCrossRef
6.
7.
go back to reference Allanore Y, Borderie D, Meune C et al (2003) N-terminal pro-brain natriuretic peptide as a diagnostic marker of early pulmonary artery hypertension in patients with systemic sclerosis and effects of calcium-channel blockers. Arthritis Rheum 48:3503–3508PubMedCrossRef Allanore Y, Borderie D, Meune C et al (2003) N-terminal pro-brain natriuretic peptide as a diagnostic marker of early pulmonary artery hypertension in patients with systemic sclerosis and effects of calcium-channel blockers. Arthritis Rheum 48:3503–3508PubMedCrossRef
8.
go back to reference Murkerjee D, Yap LB, Holmes AM et al (2003) Significance of plasma N-terminal pro-brain natriuretic peptide in patients with systemic sclerosis-related pulmonary arterial hypertension. Resp Med 97:1230–1236CrossRef Murkerjee D, Yap LB, Holmes AM et al (2003) Significance of plasma N-terminal pro-brain natriuretic peptide in patients with systemic sclerosis-related pulmonary arterial hypertension. Resp Med 97:1230–1236CrossRef
9.
go back to reference Hesselstrand R, Ekman R, Eskilsson J et al (2005) Screening for pulmonary hypertension in systemic sclerosis; the longitudinal development of tricuspid gradient in 227 consecutive patients, 1992–2001. Rheumatology 44:366–371PubMedCrossRef Hesselstrand R, Ekman R, Eskilsson J et al (2005) Screening for pulmonary hypertension in systemic sclerosis; the longitudinal development of tricuspid gradient in 227 consecutive patients, 1992–2001. Rheumatology 44:366–371PubMedCrossRef
10.
go back to reference Dimitroulas T, Giannakoulas G, Karvounis H (2006) Neurohormonal activation in patients with systemic sclerosis-related pulmonary arterial hypertension. Int J Cardiol 121(1):135–137PubMedCrossRef Dimitroulas T, Giannakoulas G, Karvounis H (2006) Neurohormonal activation in patients with systemic sclerosis-related pulmonary arterial hypertension. Int J Cardiol 121(1):135–137PubMedCrossRef
11.
go back to reference Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee (1980) Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 23:581–590CrossRef Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee (1980) Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 23:581–590CrossRef
12.
go back to reference LeRoy EC, Krieg T, Black C et al (1988) Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 15:202–205PubMed LeRoy EC, Krieg T, Black C et al (1988) Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 15:202–205PubMed
13.
go back to reference Chobanian AV, Bakris GL, Black HR et al (2003) The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 289:2560–2572PubMedCrossRef Chobanian AV, Bakris GL, Black HR et al (2003) The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 289:2560–2572PubMedCrossRef
14.
go back to reference Ooi GC, Mok MY, Tsang KWT et al (2003) Interstitial lung disease in systemic sclerosis an HRCT-clinical correlative study. Acta Radiologica 44:258–264PubMedCrossRef Ooi GC, Mok MY, Tsang KWT et al (2003) Interstitial lung disease in systemic sclerosis an HRCT-clinical correlative study. Acta Radiologica 44:258–264PubMedCrossRef
15.
go back to reference Remy-Jardin M, Giraud F, Remy J, Copin MC et al (1993) Importance of ground-glass attenuation in chronic diffuse infiltrative lung disease: pathologic-CT correlation. Radiology 189:693–698PubMed Remy-Jardin M, Giraud F, Remy J, Copin MC et al (1993) Importance of ground-glass attenuation in chronic diffuse infiltrative lung disease: pathologic-CT correlation. Radiology 189:693–698PubMed
16.
go back to reference Yeo KTJ, Wu AHB, Apple FS et al (2003) Multicenter evaluation of the Roche NT-proBNP assay and comparison to the Biosite Triage BNP assay. Clin Chim Acta 338:107–115PubMedCrossRef Yeo KTJ, Wu AHB, Apple FS et al (2003) Multicenter evaluation of the Roche NT-proBNP assay and comparison to the Biosite Triage BNP assay. Clin Chim Acta 338:107–115PubMedCrossRef
17.
go back to reference Hammerer-Lercher A, Neubauer E, Muller S et al (2001) Head-to head comparison of N-terminal pro-brain natriuretic peptide, brain natriuretic peptide and N-terminal pro-atrial natriuretic peptide in diagnosing left ventricular dysfunction. Clin Chim Acta 310:193–197PubMedCrossRef Hammerer-Lercher A, Neubauer E, Muller S et al (2001) Head-to head comparison of N-terminal pro-brain natriuretic peptide, brain natriuretic peptide and N-terminal pro-atrial natriuretic peptide in diagnosing left ventricular dysfunction. Clin Chim Acta 310:193–197PubMedCrossRef
18.
go back to reference Hesselstrand R, Scheja A, Akesson A (1998) Mortality and causes of death in a Swedish series of systemic sclerosis patients. Ann Rheum Dis 57:682–686PubMedCrossRef Hesselstrand R, Scheja A, Akesson A (1998) Mortality and causes of death in a Swedish series of systemic sclerosis patients. Ann Rheum Dis 57:682–686PubMedCrossRef
19.
go back to reference Rhew EY, Barr WG (2004) Scleroderma renal crisis: new insights and developments. Curr Rheumatol Rep 6:129–136PubMedCrossRef Rhew EY, Barr WG (2004) Scleroderma renal crisis: new insights and developments. Curr Rheumatol Rep 6:129–136PubMedCrossRef
20.
go back to reference Nagaya N, Nishikimi T, Uematsu M et al (2000) Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation 102:865–870PubMed Nagaya N, Nishikimi T, Uematsu M et al (2000) Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation 102:865–870PubMed
21.
go back to reference Morgan C, Knight C, Lunt M et al (2003) Predictors of end stage lung disease in a cohort of patients with scleroderma. Ann Rheum Dis 62:146–150PubMedCrossRef Morgan C, Knight C, Lunt M et al (2003) Predictors of end stage lung disease in a cohort of patients with scleroderma. Ann Rheum Dis 62:146–150PubMedCrossRef
22.
go back to reference Steen VD, Conte C, Owens GR et al (1994) Severe restrictive lung disease in systemic sclerosis. Arthritis Rheum 37:1283–1289PubMedCrossRef Steen VD, Conte C, Owens GR et al (1994) Severe restrictive lung disease in systemic sclerosis. Arthritis Rheum 37:1283–1289PubMedCrossRef
23.
go back to reference Steen VD, Graham G, Conte C et al (1992) Isolated diffusing capacity reduction in systemic sclerosis. Arthritis Rheum 35:765–770PubMedCrossRef Steen VD, Graham G, Conte C et al (1992) Isolated diffusing capacity reduction in systemic sclerosis. Arthritis Rheum 35:765–770PubMedCrossRef
24.
go back to reference Raymond I, Groenning BA, Hildebrandt PR et al (2003) The influence of age, sex and other variables on the plasma level of N-terminal pro-brain natriuretic peptide in a large sample of the general population. Heart 89:745–751PubMedCrossRef Raymond I, Groenning BA, Hildebrandt PR et al (2003) The influence of age, sex and other variables on the plasma level of N-terminal pro-brain natriuretic peptide in a large sample of the general population. Heart 89:745–751PubMedCrossRef
25.
go back to reference Hobbs FDR, Davis RC, Roalfe AK et al (2002) Reliability of N-terminal pro-brain natriuretic peptide assay in diagnosis of heart failure; cohort study in representative and high risk community populations. BMJ 324:1–5CrossRef Hobbs FDR, Davis RC, Roalfe AK et al (2002) Reliability of N-terminal pro-brain natriuretic peptide assay in diagnosis of heart failure; cohort study in representative and high risk community populations. BMJ 324:1–5CrossRef
26.
27.
go back to reference Montagnana M, Lippi G, Volpe A et al (2006) Evaluation of cardiac laboratory markers in patients with systemic sclerosis. Clin Biochem 39:913–917PubMedCrossRef Montagnana M, Lippi G, Volpe A et al (2006) Evaluation of cardiac laboratory markers in patients with systemic sclerosis. Clin Biochem 39:913–917PubMedCrossRef
Metadata
Title
The clinical significance of serum N-terminal pro-brain natriuretic peptide in systemic sclerosis patients
Authors
Hyo Jin Choi
Young Kee Shin
Hyun Joo Lee
Joo Young Kee
Dong Woo Shin
Eun Young Lee
Yun Jong Lee
Eun Bong Lee
Yeong Wook Song
Publication date
01-04-2008
Publisher
Springer-Verlag
Published in
Clinical Rheumatology / Issue 4/2008
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-007-0724-9

Other articles of this Issue 4/2008

Clinical Rheumatology 4/2008 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.